健康科学杂志

  • 国际标准期刊号: 1108-7366
  • 期刊 h 指数: 51
  • 期刊引用分数: 10.69
  • 期刊影响因子: 9.13
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • CINAHL 完整
  • 西马戈
  • 电子期刊图书馆
  • 研究期刊索引目录 (DRJI)
  • EMCare
  • OCLC-WorldCat
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
分享此页面

抽象的

Cardiovascular System and SARS-COV-2 – Etiology, Physiopathology and Clinical Presentation: a Systematic Review

Lucas de Alencar Viana Melo, Wantuil Matias Neto and Modesto Leite Rolim Neto

Background: During SARS-CoV-1 and MiddleEast Respiratory Distress Syndrome (MERS) outbreaks, a particularlyelevated incidence of cardiovascular disease among patients was observed. With COVID-19, this correlation becomes evident again. However, the cardiovascular impacts by COVID-19 pandemic are not yet well established although there are constant publications about its potential deleterious effects. Thus, we aimed to carry a systematic review of the literature with meta-analysis based on thefollowing guiding question: what practical contributionsto the scientific literature produced in theperiod of 2019-2020 does the impact of the COVID-19 on cardiovascular system have to offer?

Methods: A systematic review of the literature using the Virtual Health Library (VHL) and PubMed with the following descriptors: #1 "cardiovascular disease" [MeSH] AND #2 "COVID-19" [keyword], as well as their equivalents in the Portuguese and Spanish language, during the period from December 2019 to March 2020 was performed.

Results: one hundred articles are found in Pubmed and twenty-seven are selected. In VHL there were 59 articles and four are selected totaling thirty-one papers. The findings were then divided into three subcategories: Etiology, Physiopathology and Risk factors of SARS-CoV-2 in Cardiovascular System; Clinical presentation, laboratory markers and imagenological aspects of SARS-CoV-2 in cardiovascular system; and Anti- Hypertensive Drugs, Cardiovascular System and SARS-CoV-2.

Conclusions: It comes to the cardiovascular system, these issues are aggravated and urge as a joint commitment from researchers, medical and governmental organizations for carry out more robust studies with bold methodologies aimed at mapping prognostic factors and assertive therapeutic approaches in the management of cardiovascular complications of COVID- 19.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证